Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline

With Biogen’s multiple sclerosis portfolio facing more generic pressure than ever, the company is eyeing a busy late-stage pipeline and hunting for deals to build its return to growth.